Announced
Completed
Financials
Tags
United Kingdom
clinical-stage
Private
Pharmaceuticals
Cross Border
Acquisition
Friendly
Majority
Private Equity
Single Bidder
Completed
Synopsis
Pfizer, an American multinational pharmaceutical and biotechnology corporation, completed the acquisition of ReViral, a clinical-stage biopharmaceutical company, from Novo, a private limited liability company, and Andera Partners, a private equity firm, for $525m. "Currently, treatment options for RSV are extremely limited and focus primarily on supportive care. The proposed acquisition of ReViral’s pipeline of therapeutic candidates is complementary to our efforts to advance the first vaccine candidate to help protect against this harmful disease. Combining the capabilities and expertise of our organizations will enable us to further the clinical development of a potential therapy for those with RSV disease," Annaliesa Anderson, Pfizer Senior Vice President and Chief Scientific Officer.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.